BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//DataCutoff//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:DataCutoff · $SRPT readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by DataCutoff. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05881408-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:ENVISION readout (P3) · Sarepta Therapeutics\, Inc. $SRPT
DESCRIPTION:A Gene Transfer Therapy Study to Evaluate the Safety and Effica
 cy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambula
 tory Participants With Duchenne Muscular D…\n\nPrimary completion date: 
 2027-05-31 (estimated)\nOriginally planned: 2026-01-31 (+15.9 months)\nPha
 se 3 · Rare · Duchenne Muscular Dystrophy\nEnrollment: 148 · Sites: 46\
 n\nPrimary completion = last participant's primary-endpoint data collected
 \; topline results usually follow weeks to months later. Sponsor-reported\
 , often an estimate. Not investment advice.\n\nhttps://datacutoff.com/rada
 r.html?nct=NCT05881408\nhttps://clinicaltrials.gov/study/NCT05881408
URL:https://datacutoff.com/radar.html?nct=NCT05881408
CATEGORIES:Rare,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
